Related Experiment Video
Updated: Jul 9, 2025
06:57
Transaxillary First Rib Resection for Treatment of the Thoracic Outlet Syndrome
Published on: September 13, 2020
3.0K
Stepwise Treatment for TAFRO Syndrome.
Makoto Ide1, Tomoko Yokoyama2, Masashi Ishikawa3
1Department of Hematology, Takamatsu Red Cross Hospital, Takamatsu, Kagawa, Japan.
Journal of Medical Cases
|November 29, 2023
Summary
TAFRO syndrome, a rare fatal disease, may respond to a stepwise immunotherapy approach. Combining rituximab induction with cyclosporine maintenance showed promise in one patient, but outcomes varied in another case.
Area of Science:
- Hematology
- Immunology
- Rare Diseases
Background:
- TAFRO syndrome is a rare, rapidly progressive, and often fatal condition with unknown etiology.
- It shares features with Castleman disease (CD), often treated with anti-interleukin-6 or rituximab.
- The efficacy of these treatments in TAFRO syndrome is not well-established.
Related Concept Videos
01:28Pulmonary Tuberculosis V
181
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
181
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
174
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
174